Charité N Ricker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2691979/publications.pdf

Version: 2024-02-01

567281 580821 25 814 15 25 citations h-index g-index papers 30 30 30 1296 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1666-1671.	2.5	157
2	Prevalence and Type of <i>BRCA</i> Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. Journal of Clinical Oncology, 2013, 31, 210-216.	1.6	140
3	Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. Cancer Genetics, 2016, 209, 130-137.	0.4	68
4	If We Build It … Will They Come? – Establishing a Cancer Genetics Services Clinic for an Underserved Predominantly Latina Cohort. Journal of Genetic Counseling, 2006, 15, 505-514.	1.6	59
5	Genomic Disparities in Breast Cancer among Latinas. Cancer Control, 2016, 23, 359-372.	1.8	46
6	Socialâ€cognitive aspects of underserved Latinas preparing to undergo genetic cancer risk assessment for hereditary breast and ovarian cancer. Psycho-Oncology, 2008, 17, 774-782.	2.3	45
7	Patient communication of cancer genetic test results in a diverse population. Translational Behavioral Medicine, 2018, 8, 85-94.	2.4	34
8	Beliefs and interest in cancer risk in an underserved Latino cohort. Preventive Medicine, 2007, 44, 241-245.	3.4	32
9	Outcomes from intensive training in genetic cancer risk counseling for clinicians. Genetics in Medicine, 2005, 7, 40-47.	2.4	31
10	Unexpected <i>CDH1</i> Mutations Identified on Multigene Panels Pose Clinical Management Challenges. JCO Precision Oncology, 2017, 1, 1-12.	3.0	29
11	Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series. Gynecologic Oncology Reports, 2018, 25, 98-101.	0.6	23
12	Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precision Oncology, 2019, 3, 1-12.	3.0	23
13	Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Cancer, 2021, 127, 1275-1285.	4.1	21
14	DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer, 2017, 123, 3732-3743.	4.1	19
15	Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromesâ€"Practice resource of the National Society of Genetic Counselors. Journal of Genetic Counseling, 2021, 30, 342-360.	1.6	18
16	Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Research and Treatment, 2011, 130, 281-289.	2.5	17
17	A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors. Journal of Genetic Counseling, 2021, 30, 394-405.	1.6	13
18	Development and pilot testing of a training for bilingual community education professionals about hereditary breast and ovarian cancer among Latinas: <i>ÃRBOLES Familiares</i> Rehavioral Medicine, 2022, 12, .	2.4	10

#	Article	IF	CITATIONS
19	Closing the loop: an interactive action-research conference format for delivering updated medical information while eliciting Latina patient/family experiences and psychosocial needs post-genetic cancer risk assessment. Familial Cancer, 2012, 11, 449-458.	1.9	9
20	Transcriptome analysis provides critical answers to the "variants of uncertain significance― conundrum. Human Mutation, 2022, 43, 1590-1608.	2.5	7
21	Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. Frontiers in Oncology, 2018, 8, 259.	2.8	5
22	Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. Gynecologic Oncology, 2020, 159, 869-876.	1.4	3
23	Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation. BMJ Case Reports, 2019, 12, e227625.	0.5	2
24	FROM FAMILIES SYNDROMES TO GENES… THE FIRST CLINICAL AND GENETIC CHARACTERIZATIONS OF HEREDITARY SYNDROMES PREDISPOSING TO CANCER: WHAT WAS THE BEGINNING?. Revista Médica ClÃnica Las Condes, 2017, 28, 482-490.	0.2	1
25	Uptake of surgical prophylaxis in underserved, ethnic minority BRCA mutation carriers Journal of Clinical Oncology, 2012, 30, 45-45.	1.6	O